Zetia vs Repatha: Switching Between Ezetimibe and Evolocumab

How Each Drug Lowers LDL

Ezetimibe and evolocumab attack cholesterol metabolism at completely different points, which is why they can be used together and why switching between them is pharmacologically straightforward.

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by about 54% [1]. This triggers a compensatory upregulation of hepatic LDL receptors. The net effect is an additional 18 to 25% LDL reduction when added to a statin. Because the drug is absorbed orally and reaches steady-state plasma concentrations within about 2 weeks, it is a low-barrier addition to statin therapy.

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally tags LDL receptors on hepatocytes for degradation. By blocking that tagging, evolocumab allows LDL receptors to recycle back to the cell surface, pulling more LDL particles out of circulation [2]. The result is a roughly 59% reduction in LDL cholesterol on top of statin therapy, a magnitude that dwarfs what ezetimibe can achieve alone.

Both drugs are well-tolerated. Ezetimibe's side-effect profile in IMPROVE-IT was nearly identical to placebo [1]. Evolocumab's safety data through the FOURIER open-label extension (median 5 years of exposure) showed no signal for neurocognitive effects, new-onset diabetes, or muscle-related adverse events beyond background rates [3].

Trial Evidence: IMPROVE-IT and FOURIER

No head-to-head randomized trial has directly compared ezetimibe with evolocumab. The two landmark trials tested each drug against placebo (on top of statins), so any comparison requires cross-trial interpretation with all the limitations that entails.

IMPROVE-IT (N=18,144) enrolled patients within 10 days of an acute coronary syndrome (ACS) event and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo [1]. Over a median follow-up of 6 years, the ezetimibe group had a 6.4% relative reduction in the primary composite endpoint of cardiovascular death, major coronary events, and nonfatal stroke (hazard ratio 0.936 to 95% CI 0.89 to 0.99, P=0.016). Mean LDL dropped to 53.7 mg/dL in the ezetimibe arm versus 69.5 mg/dL in the placebo arm. That 16 mg/dL absolute LDL difference produced a modest but statistically significant benefit over 7 years.

FOURIER (N=27,564) enrolled patients with stable atherosclerotic cardiovascular disease (ASCVD) already on optimized statin therapy and randomized them to evolocumab or placebo [2]. At 48 weeks, evolocumab reduced LDL from a median baseline of 92 mg/dL to 30 mg/dL. Over a median follow-up of 2.2 years, the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001).

The absolute LDL reductions tell a clear story. Evolocumab produced a 59% drop from baseline; ezetimibe produced roughly 24%. Dr. Robert Giugliano, co-principal investigator of IMPROVE-IT, noted in a 2018 review: "The magnitude of LDL-C reduction determines the magnitude of cardiovascular benefit, consistent with the Cholesterol Treatment Trialists' meta-analysis showing a proportional 22% reduction in major vascular events per 1 mmol/L LDL-C lowering" [4].

When to Add Ezetimibe First

The 2018 AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol establishes a clear stepwise algorithm for patients who do not reach their LDL goal on maximally tolerated statin therapy [5]. Ezetimibe occupies the second rung of that ladder, ahead of PCSK9 inhibitors. The reasoning is practical.

Ezetimibe costs between $10 and $20 per month as a generic. It requires no injections, no prior authorizations in most formularies, and no cold-chain storage. For patients with ASCVD whose LDL remains at or above 70 mg/dL on a high-intensity statin, adding ezetimibe can push LDL below that threshold without changing the daily routine beyond swallowing one more pill.

The guideline specifies that for patients at very high ASCVD risk (those with a history of multiple major events or one major event plus multiple high-risk conditions), an LDL target of <70 mg/dL is reasonable, and if ezetimibe does not achieve that, a PCSK9 inhibitor should be considered [5]. The 2022 ACC Expert Consensus Decision Pathway for the role of nonstatin therapies reinforced this approach, specifically naming ezetimibe as the preferred nonstatin addition before PCSK9 inhibitors [6].

Dr. Donald Lloyd-Jones, chair of the 2018 guideline writing committee, stated in the accompanying commentary: "We recommend a stepwise approach that begins with lifestyle, then statins at appropriate intensity, then ezetimibe, and only then consideration of a PCSK9 inhibitor, because each step carries incrementally higher cost and complexity" [5].

When Switching to Repatha Makes Sense

There are three clinical scenarios where moving from ezetimibe to evolocumab (or adding evolocumab on top of ezetimibe) is warranted based on published guidelines and trial data.

Scenario 1: LDL still above threshold despite statin plus ezetimibe. A patient with clinical ASCVD on rosuvastatin 40 mg and ezetimibe 10 mg whose LDL remains at 85 mg/dL has exhausted oral options. Adding evolocumab in this setting is supported by FOURIER subgroup analyses showing consistent benefit regardless of baseline LDL [2]. The expected additional LDL drop would bring that patient to approximately 35 mg/dL.

Scenario 2: Statin intolerance with residual high LDL. Some patients cannot tolerate any statin dose. These patients may be placed on ezetimibe monotherapy, but ezetimibe alone reduces LDL by only about 18%. If LDL remains dangerously elevated (for example, above 100 mg/dL in a patient with ASCVD), evolocumab monotherapy or evolocumab plus ezetimibe becomes the clinically appropriate combination. The GAUSS-3 trial (N=511) specifically studied evolocumab in statin-intolerant patients and found a 52.8% LDL reduction versus ezetimibe's 16.7% reduction over 24 weeks [7].

Scenario 3: Familial hypercholesterolemia (FH). Patients with heterozygous FH often have baseline LDL values above 190 mg/dL. Even with a high-intensity statin and ezetimibe, many remain above 100 mg/dL. The RUTHERFORD-2 trial demonstrated that evolocumab reduced LDL by 59.2% in heterozygous FH patients already on lipid-lowering therapy [8]. For these patients, adding or switching to evolocumab is not optional but medically necessary.

How to Make the Switch: Practical Pharmacology

Switching from ezetimibe to evolocumab requires no washout period. Ezetimibe has a half-life of approximately 22 hours, and its metabolite ezetimibe-glucuronide has a half-life of about 22 hours as well [9]. Neither compound interferes with PCSK9 inhibitor pharmacokinetics.

In clinical practice, the transition works one of two ways. A clinician may discontinue ezetimibe and initiate evolocumab at 140 mg every 2 weeks or 420 mg once monthly by subcutaneous injection. Alternatively, and more commonly in high-risk patients, the clinician may keep ezetimibe in place and add evolocumab on top of it. The FOURIER trial allowed concomitant ezetimibe use: approximately 5.2% of enrolled patients were on ezetimibe at baseline, and evolocumab's efficacy was maintained in this subgroup [2].

A practical timeline for the switch looks like this. At the initial visit, confirm that the patient is on maximally tolerated statin plus ezetimibe and that LDL remains above the target after at least 4 to 6 weeks. Order a fasting lipid panel to establish the pre-switch baseline. Submit a prior authorization for evolocumab (most commercial insurers and Medicare Part D plans require documentation of statin plus ezetimibe failure). Once approved, the first evolocumab injection can be administered in-office or self-injected at home using the SureClick autoinjector. Recheck LDL 4 to 8 weeks after the first dose, by which point evolocumab reaches steady-state effect [10].

If the patient is switching to evolocumab without continuing ezetimibe (for example, to simplify the regimen), ezetimibe can be stopped on the same day as the first evolocumab injection. There is no rebound in LDL from ezetimibe discontinuation because the drug does not alter hepatic cholesterol synthesis pathways the way statins do.

Cost, Access, and Insurance Realities

The economic gap between these drugs is enormous. Generic ezetimibe costs $10 to $20 per month at most retail pharmacies. Evolocumab's list price is approximately $6,600 per year, though Amgen's patient assistance programs and manufacturer copay cards can reduce out-of-pocket costs to as low as $5 per month for eligible commercially insured patients [11].

Most insurers require a step-therapy protocol before covering evolocumab. The typical documentation package includes: (1) confirmation of ASCVD or FH diagnosis, (2) demonstration of maximally tolerated statin therapy, (3) evidence that ezetimibe has been tried for at least 8 to 12 weeks without achieving LDL goal, and (4) two fasting LDL values separated by at least 4 weeks. Medicare Part D plans follow similar requirements, though specific formulary tiers vary by plan.

The 2023 Institute for Clinical and Economic Review (ICER) re-evaluation of PCSK9 inhibitors found that at their current net prices (after rebates), both evolocumab and alirocumab approach cost-effectiveness thresholds of $100,000 to $150,000 per quality-adjusted life year (QALY) for high-risk ASCVD patients with LDL above 70 mg/dL despite maximally tolerated statin plus ezetimibe [12]. This represented a significant improvement from ICER's 2017 assessment, largely driven by Amgen's 60% list-price reduction in 2018.

Combining Both Drugs: Triple Non-Statin Therapy

For patients requiring maximum LDL suppression, the combination of a statin, ezetimibe, and evolocumab is not only pharmacologically rational but increasingly common in clinical practice. Each drug targets a distinct node in cholesterol metabolism: statins inhibit HMG-CoA reductase (hepatic synthesis), ezetimibe blocks intestinal absorption, and evolocumab prevents LDL-receptor degradation.

A post hoc analysis of FOURIER participants who were on statin plus ezetimibe at baseline showed that adding evolocumab reduced LDL by an additional 57% from an already-lowered starting point [2]. Some of these patients achieved LDL values below 10 mg/dL. The EBBINGHAUS cognitive substudy (N=1,974) found no association between very low achieved LDL levels and neurocognitive decline over a median of 19 months [13].

The 2022 European Atherosclerosis Society consensus statement on the use of very low LDL-C targets acknowledged that "there is no lower LDL-C threshold below which benefit ceases or harm begins, based on available trial and genetic data" [14]. This gives clinicians confidence to push LDL as low as pharmacologically possible in patients with recurrent events or extremely high baseline cardiovascular risk.

Safety and Side Effects Compared

Both medications carry favorable safety profiles, though their adverse-event patterns differ.

Ezetimibe's most commonly reported side effects include upper respiratory tract infection (4.3%), diarrhea (3.7%), and arthralgia (3.0%), rates that were virtually identical to placebo in IMPROVE-IT [1]. Rare post-marketing reports include hepatitis and pancreatitis, though causality has not been established. Ezetimibe is contraindicated in combination with a statin during pregnancy (FDA Category X for the combination). A notable absence: ezetimibe does not cause myalgia at rates above placebo, making it an attractive option for statin-intolerant patients.

Evolocumab's most common side effects in FOURIER were nasopharyngitis (10.3%), upper respiratory tract infection (9.3%), and injection-site reactions (2.1%) [2]. Anti-drug antibodies developed in 0.3% of patients but were not associated with reduced efficacy or increased adverse events. The long-term open-label extension (OSLER-1, median 5 years) confirmed sustained safety with no increased risk of diabetes, cancer, or neurocognitive events compared to background population rates [3].

One practical difference matters for patient experience. Ezetimibe is a small, once-daily pill. Evolocumab requires a subcutaneous injection, either every 2 weeks (one 140 mg injection) or once monthly (three 140 mg injections or one 420 mg dose via the Pushtronex system). Injection-site reactions are mild (erythema, pain, bruising) and decline in frequency after the first few months.

What the Guidelines Recommend Right Now

The current American consensus, updated in the 2022 ACC Expert Consensus Decision Pathway, is unambiguous [6]. For secondary prevention in patients with clinical ASCVD:

1. Start with high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg).
2. If LDL remains at or above 70 mg/dL after 4 to 6 weeks, add ezetimibe 10 mg.
3. If LDL remains above threshold after an additional 4 to 6 weeks on ezetimibe, add a PCSK9 inhibitor (evolocumab 140 mg every 2 weeks or alirocumab 75 mg every 2 weeks).

For primary prevention in patients with LDL persistently above 190 mg/dL (presumed FH), the pathway is similar but with lower cost barriers after the FDA's 2021 expanded indication for evolocumab in primary hyperlipidemia.

The European Society of Cardiology's 2019 dyslipidemia guidelines recommend an LDL target of <55 mg/dL for very-high-risk patients and <40 mg/dL for those with recurrent events within 2 years, targets that frequently require all three drug classes [15].

Patients currently on ezetimibe who experience a cardiovascular event while on therapy should be reassessed for PCSK9 inhibitor eligibility within 4 to 8 weeks. The 2022 ACC Pathway specifically flags recent ACS as a trigger to accelerate the step-up to evolocumab rather than waiting for a second LDL measurement on the current regimen [6].